Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14681055 | 1.00 | GBA1 (0.64) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL18462060 | 0.98 | GBA1 (0.62) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL19501713 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL11318961 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL19663777 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL24675720 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL15944228 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL94371 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL21959579 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL15203072 | 0.96 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170247423-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2017-08-31 | — | — | US | disclosed |
| EP-2564863-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | NASH HUW M | 2011-10-13 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | GBA1 4720/4885HRH4 1260/4885HRH3 1800/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GBA1 4570/4885HRH4 1806/4885HRH3 1158/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | GBA1 1017/4885HRH4 4083/4885HRH3 3193/4885 |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GBA1 280/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | GBA1 2917/4885HRH4 4179/4885HRH3 4144/4885 |
| US-20170247423-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | GBA1 1462/4885HRH4 3426/4885HRH3 2932/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GBA1 2752/4885HRH4 4334/4885HRH3 3879/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | GBA1 998/4885HRH4 2978/4885HRH3 2750/4885 |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | SLC29A2, SLC29A1, SLC22A3 | GBA1 568/4885HRH4 4816/4885HRH3 3990/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GBA1 280/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GBA1 2752/4885HRH4 4334/4885HRH3 3879/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GBA1 2876/4885HRH4 3022/4885HRH3 2281/4885 |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | GBA1 2876/4885HRH4 3022/4885HRH3 2281/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | GBA1 1054/4885HRH4 2338/4885HRH3 1911/4885 |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GBA1 669/4885HRH4 1851/4885HRH3 2016/4885 |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | GBA1 552/4885HRH4 1804/4885HRH3 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.